Other Events ·
Pulse Biosciences, Inc. announced on July 29, 2026, that its NANOPULSE-AF clinical study has surpassed the enrollment…
PLSEPulse Biosciences, Inc.
Pulse Biosciences, Inc. announced on July 29, 2026, that its NANOPULSE-AF clinical study has surpassed the enrollment midpoint. The prospective, multicenter pivotal investigation evaluates the Company’s nPulse™ Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation. The study commenced in April 2026 and is expected to enroll patients at up to 30 sites globally. Pulse Biosciences operates in the medical device industry, developing nanosecond pulsed field ablation technology for cardiac arrhythmia treatment.